Literature DB >> 24489090

IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.

Lauren M F Merlo1, Elizabeth Pigott1, James B DuHadaway1, Samantha Grabler1, Richard Metz2, George C Prendergast1,3,4, Laura Mandik-Nayak1,5.   

Abstract

Rheumatoid arthritis and other autoimmune disorders are associated with altered activity of the immunomodulatory enzyme IDO. However, the precise contributions of IDO function to autoimmunity remain unclear. In this article, we examine the effect of two different IDO enzymes, IDO1 and IDO2, on the development of autoimmune arthritis in the KRN preclinical model of rheumatoid arthritis. We find that IDO2, not IDO1, is critical for arthritis development, providing direct evidence of separate in vivo functions for IDO1 and IDO2. Mice null for Ido2 display decreased joint inflammation relative to wild-type mice owing to a reduction in pathogenic autoantibodies and Ab-secreting cells. Notably, IDO2 appears to specifically mediate autoreactive responses, but not normal B cell responses, as total serum Ig levels are not altered and IDO2 knockout mice are able to mount productive Ab responses to model Ags in vitro and in vivo. Reciprocal adoptive transfer studies confirm that autoantibody production and arthritis are modulated by IDO2 expression in a cell type extrinsic to the T cell. Taken together, our results, provide important insights into IDO2 function by defining its pathogenic contributions to autoantibody-mediated autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24489090      PMCID: PMC3947779          DOI: 10.4049/jimmunol.1303012

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

Review 1.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Th17 cells can provide B cell help in autoantibody induced arthritis.

Authors:  Cynthia L Hickman-Brecks; Jennifer L Racz; Debra M Meyer; Timothy P LaBranche; Paul M Allen
Journal:  J Autoimmun       Date:  2010-11-13       Impact factor: 7.094

3.  Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts.

Authors:  Hua Yang; Ruchuang Ding; Vijay K Sharma; Fludd Saint Hilaire; Milagros Lagman; Baogui Li; Dolca A Thomas; Dolea A Thomas; Xunrong Luo; Ping Song; Craig Stauffer; Phyllis August; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2007-06-27       Impact factor: 4.939

Review 4.  Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later.

Authors:  Gregory F Oxenkrug
Journal:  Isr J Psychiatry Relat Sci       Date:  2010       Impact factor: 0.481

5.  Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season.

Authors:  M Pertovaara; T Hasan; A Raitala; S S Oja; U Yli-Kerttula; M Korpela; M Hurme
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

6.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

7.  Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

Authors:  Mark C Genovese; James D McKay; Evgeny L Nasonov; Eduardo F Mysler; Nilzio A da Silva; Emma Alecock; Thasia Woodworth; Juan J Gomez-Reino
Journal:  Arthritis Rheum       Date:  2008-10

8.  Indoleamine 2,3-dioxygenase activation and depressive symptoms: results from the Young Finns Study.

Authors:  Marko Elovainio; Mikko Hurme; Markus Jokela; Laura Pulkki-Råback; Mika Kivimäki; Mirka Hintsanen; Taina Hintsa; Terho Lehtimäki; Jorma Viikari; Olli T Raitakari; Liisa Keltikangas-Järvinen
Journal:  Psychosom Med       Date:  2012-08-28       Impact factor: 4.312

9.  A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+CD25- T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice.

Authors:  Eunkyeong Jang; Sin-Hye Cho; Hyunjoo Park; Doo-Jin Paik; Jung Mogg Kim; Jeehee Youn
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

10.  IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.

Authors:  Richard Metz; Sonja Rust; James B Duhadaway; Mario R Mautino; David H Munn; Nicholas N Vahanian; Charles J Link; George C Prendergast
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

View more
  49 in total

1.  Differential expression and regulation of Ido2 in the mouse uterus during peri-implantation period.

Authors:  Dang-Dang Li; Xin-Yuan Liu; Chuan-Hui Guo; Liang Yue; Zhan-Qing Yang; Hang Cao; Bin Guo; Zhan-Peng Yue
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-11-19       Impact factor: 2.416

Review 2.  Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology.

Authors:  Mads Hald Andersen
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection.

Authors:  J S Young; J Chen; M L Miller; V Vu; C Tian; J J Moon; M-L Alegre; R Sciammas; A S Chong
Journal:  Am J Transplant       Date:  2016-04-04       Impact factor: 8.086

Review 4.  Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Xiu-Xiu Wang; Si-Yu Sun; Qing-Qing Dong; Xiao-Xiang Wu; Wei Tang; Ya-Qun Xing
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

Review 5.  Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

Authors:  George C Prendergast; Courtney Smith; Sunil Thomas; Laura Mandik-Nayak; Lisa Laury-Kleintop; Richard Metz; Alexander J Muller
Journal:  Cancer Immunol Immunother       Date:  2014-04-08       Impact factor: 6.968

Review 6.  The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.

Authors:  Sunil Thomas; Jacques Izard; Emily Walsh; Kristen Batich; Pakawat Chongsathidkiet; Gerard Clarke; David A Sela; Alexander J Muller; James M Mullin; Korin Albert; John P Gilligan; Katherine DiGuilio; Rima Dilbarova; Walker Alexander; George C Prendergast
Journal:  Cancer Res       Date:  2017-03-14       Impact factor: 12.701

7.  Induction of indoleamine 2,3-dioxygenase by Borrelia burgdorferi in human immune cells correlates with pathogenic potential.

Authors:  Andrea C Love; Ira Schwartz; Mary M Petzke
Journal:  J Leukoc Biol       Date:  2014-11-24       Impact factor: 4.962

8.  Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

Authors:  Lauren M F Merlo; Samantha Grabler; James B DuHadaway; Elizabeth Pigott; Kaylend Manley; George C Prendergast; Lisa D Laury-Kleintop; Laura Mandik-Nayak
Journal:  Clin Immunol       Date:  2017-02-20       Impact factor: 3.969

9.  B Cell-Intrinsic IDO1 Regulates Humoral Immunity to T Cell-Independent Antigens.

Authors:  Rahul Shinde; Michiko Shimoda; Kapil Chaudhary; Haiyun Liu; Eslam Mohamed; Jillian Bradley; Sridhar Kandala; Xia Li; Kebin Liu; Tracy L McGaha
Journal:  J Immunol       Date:  2015-07-27       Impact factor: 5.422

10.  IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism.

Authors:  Lauren M F Merlo; James B DuHadaway; Samantha Grabler; George C Prendergast; Alexander J Muller; Laura Mandik-Nayak
Journal:  J Immunol       Date:  2016-04-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.